Cisplatin Selects for Multidrug-Resistant CD133+ Cells in Lung Adenocarcinoma by Activating Notch Signaling - Liu, Yu-Peng; Yang, Chih-Jen; Huang, Ming-Shyan; Yeh, Chi-Tai; Wu, Alexander T.H.; Lee, Yu-Cheng; Lai, Tsung-Ching; Lee, Chien-Hsin; Hsiao, Ya-Wen; Lu, Jean; Shen, Chia-Ning; Lu, Pei-Jung; et al. (Cancer research (Chicago, Ill.), 2013)
Keywords: AC133 Antigen; Adenocarcinoma - metabolism; Adenocarcinoma - pathology; Adenocarcinoma of Lung; Animals; Antigens, CD - biosynthesis; Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; Cell Line, Tumor; Cisplatin - pharmacology; Drug Resistance, Multiple - drug effects; Drug Resistance, Neoplasm - drug effects; Glycoproteins - biosynthesis; Humans; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Medical sciences; Neoplastic Stem Cells - drug effects; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - pathology; Peptides; Pharmacology. Drug treatments; Pneumology; Receptors, Notch - drug effects; Signal Transduction - physiology; Transplantation, Heterologous; Tumors; Tumors of the respiratory system and mediastinum; Antineoplastic agent; Lung disease; Notch receptor; Respiratory disease; Lung cancer; Malignant tumor; Bronchopulmonary adenocarcinoma; In vitro; Bronchopulmonary; Cisplatin; Cell signaling; Signal transduction; Alkylating agent; Multiple resistance; Bronchus disease; Cell; Cancer; Platinum II Complexes